Patient-reported Quality of Life outcomes in patients treated for muscle-invasive bladder cancer with radiotherapy ± chemotherapy in the BC2001 Phase III Randomised Controlled Trial by Crundwell, Malcolm
E U RO P E AN URO L OGY 7 7 ( 2 0 2 0 ) 2 6 0 – 2 6 8
avai lable at www.sciencedirect .com
journal homepage: www.europeanurology.comBladder Cancer
Patient-reported Quality of Life Outcomes in Patients Treated for
Muscle-invasive Bladder CancerwithRadiotherapy Chemotherapy
in the BC2001 Phase III Randomised Controlled TrialRobert A. Huddart a,i,*,y, Emma Hall a,y, Rebecca Lewis a, Nuria Porta a, Malcolm Crundwell b,
Peter J. Jenkins c, Christine Rawlings d, Jean Tremlett e, Leila Campani f, Carey Hendron f,
Syed A. Hussain g,z, Nicholas D. James f,h,z, on behalf of the BC2001 Investigators
a The Institute of Cancer Research, London, UK; bRoyal Devon & Exeter NHS Foundation Trust, Exeter, UK; cGloucestershire Oncology Centre, Cheltenham General
Hospital, Cheltenham, UK; d Torbay and South Devon NHS Foundation Trust, Torquay, UK; eBrighton & Sussex University Hospitals NHS Trust, Brighton, UK;
fUniversity of Birmingham, Birmingham, UK; gAcademic unit of Oncology, Department of Oncology and Metabolism, Medical School, University of Sheffield,
Sheffield, UK; hUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; iRoyal Marsden NHS Foundation Trust, London, UKArticle info
Article history:
Accepted November 5, 2019










to answer questions on-line. The EU-
ACME credits will then be attributed
automatically.
Abstract
Background: BC2001, the largest randomised trial of bladder-sparing treatment for
muscle-invasive bladder cancer, demonstrated improvement of local control and blad-
der cancer–specific survival from the addition of concomitant 5-fluorouracil and mito-
mycin C to radiotherapy.
Objective: To determine the impact of treatment on the health-related quality of life
(HRQoL) of BC2001 participants.
Design, setting, and participants: 458 UK patients with T2-T4a N0 M0 transitional cell
carcinoma of the bladder.
Intervention: Patients were randomised to the chemotherapy comparison (radiothera-
py, 178, or chemoradiotherapy, 182); and/or to the radiotherapy comparison (standard,
108, or reduced high-dose volume radiotherapy, 111).
Outcome measurements and statistical analysis: Patients completed Functional Assess-
ment of Cancer Therapy—Bladder (FACT-BL) questionnaires at baseline, end of treatment
(EoT), and 6,12, 24, 36, 48, and 60 months after radiotherapy. The primary endpoint was
change from baseline in the bladder cancer subscale (BLCS) at 12 months.
Results and limitations: Data were available for 331 (92%) and 204 (93%) participants at
baseline and for 192 (54%) and 114 (52%) at 12 months for the chemotherapy and
radiotherapy comparisons, respectively. HRQoL declined at EoT (BLCS –5.06 [99%
confidence interval: –6.12 to –4.00, p < 0.001]; overall FACT-B TOTAL score –8.22
[–10.76 to –5.68, p < 0.01]), recovering to baseline at 6 months and remaining similar
to baseline subsequently. There was no significant difference between randomised
groups at any time point.
Conclusions: Immediately following (chemo)radiotherapy, a significant proportion of
patients report declines in HRQoL,which improve to baseline after 6months. Two-thirds
of patients report stable or improved HRQoL on long-term follow-up. There is no
evidence of impairmeny Robert Huddart and Emm
z Syed A. Hussain and Nich
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Patient summary: Quality of life of bladder cancer patients treated with radiothera-
py  chemotherapy deteriorates during treatment, but improves to at least pretreat-
ment levels within 6 months. Addition of chemotherapy to radiotherapy does not affect
patient-reported quality of life.
© 2019 Published by Elsevier B.V. on behalf of European Association of Urology.
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The BC2001 trial is the largest randomised trial of
radiotherapy in muscle-invasive bladder cancer (MIBC)
conducted to date. We previously reported that addition of
chemotherapy to radiotherapy significantly improves clini-
cal outcomes without a significant increase in clinician-
reported toxicity, and that reduction of the bladder volume
exposed to high-dose radiotherapy does not impact disease
control or clinician-reported toxicity [1,2]. Here, we present
the 5-year, patient-reported, health-related quality of life
(HRQoL) outcomes of the trial.
There are few papers describing long-term toxicity or
patient-reported outcomes following bladder preservation
treatment for MIBC. Previously published studies of bladder
cancer patient–reported outcomes, though reassuring, are
limited by being retrospective in nature, and there is a
paucity of data from randomised controlled trials [3–6]. We
therefore planned a prospective assessment of patient-
reported outcomes within BC2001, using the Functional
Assessment of Cancer Therapy—Bladder (FACT-BL) ques-
tionnaire [7]. The main objective was to document the
longitudinal quality of life experience of patients undergo-
ing radical radiotherapy and to compare it between
randomised treatment groups.
2. Patients and methods
2.1. Trial design and participants
BC2001 is a phase III trial with a partial 2  2 factorial
design conducted at 45 UK hospitals. Patients with localised
MIBC were randomised 1:1 to (1) the chemotherapy
comparison, to receive radiotherapy with chemotherapy
(cRT) or without chemotherapy (RT), and could also be
randomised to (2) the radiotherapy comparison, to receive
standard whole-bladder radiotherapy (stRT) or reduced
high-dose volume radiotherapy (RHDVRT) with tumour
boost; see Supplementary Fig. 1 for trial design. Recruit-
ment to both randomisations was encouraged but optional
according to patient eligibility and preference. All partici-
pants received conformal radiotherapy on consecutive
weekdays according to the local hospital’s standard
regimen (either 55 Gy/20 fractions or 64 Gy/32 fractions).
Patients randomised to chemotherapy received intravenous
mitomycin C (12 mg/m2 [129_TD$DIFF]) on day 1 of radiotherapy and
continuous infusion of 5-fluorouracil (5-FU) 500 mg/m2/
24 h for 5 days during radiotherapy fractions 1–5 and 16–20.
Full details have been reported previously [1,2].The trial was registered (ISRCTN68324339), approved by
theNorthWestMulticentre Research Ethics Committee (00/
8/075), sponsored by the University of Birmingham, and
conducted in accordancewith the principles of good clinical
practice. All the participants provided written informed
consent. The Cancer Research UK Clinical Trials Unit at the
University of Birmingham and the Clinical Trials and
Statistics Unit at the Institute of Cancer Research (ICR-
CTSU; London, UK) shared study coordination and data
management. The ICR-CTSU conducted central statistical
data monitoring and statistical analyses.
2.2. HRQoL study
All BC2001 participants were asked to consent to the
optional HRQoL study. Questionnaires were completed in
clinic on paper at baseline, at the end of treatment, at
6 months from the end of treatment, and then annually to
5 years.
The FACT-BL questionnaire incorporates 39 items with
five-point Likert scale answers and five subscales: physical
well-being (PWB), social well-being (SWB), emotional well-
being (EWB), functional well-being (FWB), and bladder
cancer subscale (BLCS) [7]. For questions phrased negative-
ly, scoring was reversed, so high scores are indicative of
better HRQoL throughout. Scoring and management of
missing items were dealt with in accordancewith the FACIT
administration and scoring guidelines [8]. See the Supple-
mentary material (Appendix 1) for further details.
2.3. Outcomes
The primary endpoint for both the chemotherapy and
radiotherapy comparisons was the change from baseline
score in BLCS. The primary time point of interest was 1 year.
Secondary endpoints included changes from baseline in
(1) FACT-BL total score (TOTAL), generated as the sum of all
items in the FACT-BL questionnaire; (2) separate component
subscales (PWB, SWB, EWB, and FWB); (3) the Trial
Outcome Index (TOI) score (sum of PWB subscale, FWB
subscale, and BLCS); and (4) specific items within the BLCS
relating to urinary function, bowel function, and male
sexual function.
Two exploratory analyses were conducted: firstly, we
explored the impact of treatment on HRQoL at an individual
level, through a comparison of the percentage of partici-
pants experiencing a minimal clinically significant positive
or negative change from baseline. This was defined as a
three-point change in BLCS, a five-point change in TOI, and a
seven-point change in TOTAL score, with thresholds based
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the effect of pretreatment with neoadjuvant chemotherapy
was also explored in a nonrandomised comparison between
patients pretreated and those not pretreated.
2.4. Statistical analysis
BC2001 was powered around the primary endpoint of
locoregional control; HRQoL analyses were prospectively
planned as a substudy of the trial.
Analyses were performed for the (1) overall trial
population, (2) chemotherapy comparison population,
and (3) radiotherapy comparison population. All analyses
were performed on the intention-to-treat population, with
sensitivity analyses to assess robustness of the results. All
analyses were conducted with Stata version 13.1 [12].
For each randomised comparison, analysis of covari-
ance (ANCOVA) regression models were used to formally
test for a difference in the mean change from baseline,
after adjusting for alternate randomisation, radiotherapy
fractionation, and baseline score. Only patients with
paired baseline and follow-up data were included in the
analysis. A significance level of 5% was used to test for the
principal outcome measure (difference in BLCS mean
between treatment groups within each comparison at
1 year, with 95% confidence interval [CI] for the estimated
difference). Interaction between the two randomised
interventions was tested using an ANCOVAmodel fitted in
patients included in both randomisations. A 1% signifi-
cance level (and corresponding 99% CI) was used for all
other endpoints to make allowance for multiplicity in
testing.
See the Supplementarymaterial (Appendix 1) for further
details on study methods.
3. Results
3.1. Patients
Between August 2001 and April 2008, 458 BC2001
participants were recruited from 45 UK centres; 452 com-
pleted at least one HRQoL assessment. Of these,
216 patients entered the radiotherapy comparison
(107 stRT/109 RHDVRT) and 355 entered the chemothera-
py comparison (179 cRT/176 RT). A total of 119 patients
entered both comparisons. At 1 year, 114 (53%) and 192
(54%) patients in the radiotherapy and chemotherapy
comparisons, respectively, provided HRQoL data; this
represented, respectively, 68% and 70% of expected
questionnaires (Supplementary [130_TD$DIFF] able 1). Amongst patients
without 1-year or later HRQoL questionnaires, 55% had an
invasive recurrence or cystectomy before 12 months, while
amongst patients with completed 1-year questionnaires,
only 11% had an invasive event before 12 months
(Supplementary [131_TD$DIFF] ig. 2). Baseline features of patients with
and without HRQoL data at 1 year are given in Supple-
mentary [132_TD$DIFF] able 2. Patients without HRQoL datawere similar
to those with data apart from a greater frequency of
residual mass and incomplete resection at baseline.3.2. Change from baseline scores
3.2.1. Overall trial population
Table 1[133_TD$DIFF] describes the median and quartile scores for each
subscale in the FACT-BL at baseline, end of treatment, 1 year,
and 5 years.
For the whole BC2001 population, a fall in HRQoL is seen
immediately following radiotherapy in the majority of
domains (Fig. 1 [134_TD$DIFF] and Supplementary Fig. 3). There is a mean
change in BLCS score of –5.06 (99% CI: –6.12 to –4.00; p <
0.001), a mean change in the TOTAL score of –8.22 (99% CI:
–10.76 to –5.68; p < 0.001), and a mean change in the TOI
score of –9.34% (99% CI: –11.47 to –7.20; p < 0.001). By
6 months after radiotherapy, HRQoL scores have improved
and returned to baseline levels.
By 1 year, all subscales have recovered to at least baseline
levels (p > 0.01), and this is maintained or improved on
subsequent follow-up. The EWB score significantly
improves above baseline at the end of treatment, with a
mean change of 1.14 (99% CI: 0.68 to 1.61; p < 0.001), and
remains above baseline throughout follow-up.
3.2.2. Chemotherapy comparison
The primary endpoint for the chemotherapy comparison is
shown in Fig. 2A [135_TD$DIFF]. Table 2 provides the treatment differences
at 1 year for change from baseline in all subscales. For BLCS,
the adjusted difference between cRT and RT at 1 year was
0.18 (95% CI: –1.60 to 1.96; p = 0.8). No significant
differences were found in any subscale or at any time
point (Supplementary [136_TD$DIFF] ig. 4).
3.2.3. Radiotherapy comparison
For the radiotherapy comparison reported in Fig. 2B and
Table 2, the difference between stRT and RHDVRT at 1 year
in change from baseline BLCS score is 2.0 (95% CI: –0.31 to
4.33; p = 0.089). No significant differences were found in
any subscale or at any time point (Supplementary Fig. 5).
For patients included in both randomisations, there was
no evidence of an interaction effect between the two
randomised interventions in change in BLCS (p = 0.3),
TOTAL score (p = 0.3), or TOI (p = 0.4) at 1 year.
3.2.4. Pretreated patients
No detrimental impact on HRQoL was observed in those
patients who had received neoadjuvant chemotherapy prior
to trial entry (Supplementary Tables 3 and 4, and Supple-
mentary Fig. 6). Baseline scores were similar between the
patients who received neoadjuvant chemotherapy and those
who did not. There was no statistically significant difference
in change from baseline BLCS (0.93; 99% CI: –1.39 to 3.25; p =
0.3) or TOTAL (6.17; 99% CI: –0.50 to 12.85; p = 0.017)
subscales, though the estimated difference in the TOTAL score
favoured patients who had received neoadjuvant chemother-
apy compared with those who had no prior therapy.
3.3. Individual items on the BLCS
At 1 year, the percentage of participants stating that they
had “quite a bit” or “very much” trouble controlling their
Table 1 – General FACT-BL scores per subscale and time point—overall population
Baseline EoT 1 year 5 years
N Median Q1–Q3 N Median Q1–Q3 N Median Q1–Q3 N Median Q1–Q3
BLCS 421 34 29–39 349 29 24–35 242 35 30–37 109 34 31–38
TOTAL 421 124 108–133 349 115 97–130 240 126 113–137 107 127 116–136
TOI 418 80 70–88 346 71 57–83 240 82 72–90 107 83 74–89
EWB 420 20 17–22 352 21 19–23 242 21 19–23 108 22 20–24
FWB 421 21 17–25 350 19 14–24 242 22 17–26 109 22 18–26
SWB 415 25 22–28 345 25 21–27 242 25 21–28 105 24 20–27
PWB 423 25 22–27 351 24 20–26 242 26 23–27 108 26 24–27
BLCS = bladder cancer subscale; EoT = end of treatment; EWB = emotional well-being; FACT-BL = Functional Assessment of Cancer Therapy—Bladder;
FWB = functional well-being; PWB = physical well-being; Q1 = 1st quartile (25% percentile); Q3 = 3rd quartile (75% percentile); SWB = social well-being;
TOI = Trial Outcome Index; TOTAL = FACT-BL total score.
[(Fig._1)TD$FIG]
Fig. 1 – Mean change from baseline (with 99% confidence intervals) in FACT-BL BLCS, TOI, and TOTAL scores for overall population. B/L = baseline;
BLCS = bladder cancer subscale; CI = confidence interval; EoT = end of treatment; FACT-BL = Functional Assessment of Cancer Therapy—Bladder;
TOI = Trial Outcome Index; TOTAL = FACT-BL total score.
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was 25% (baseline 34%), not having control of their bowels
was 14% (baseline 12%), and having diarrhoea was 2.1%
(baseline 1.2%). Amongst males, the percentage being able
to have or maintain an erection (“quite a bit” or “very
much”) was 20% (baseline 24%). Fig. 3 [137_TD$DIFF] reports the
percentages for all items and all time points in the
overall population. Similar proportions were found in the
treatment arms of the randomised comparisons (Supple-
mentary Fig. 7).3.4. Impact of treatment on individuals
As expected from themean scores, in the overall population, a
substantial proportion of participants reported worsening of
HRQoL at the end of treatment (Fig. 4A [138_TD$DIFF]). On the BLCS score,
59% reportedworsening of symptoms at the end of treatment,
similar to the pattern seen with the TOI score, while 49%
reported worsening symptoms in the TOTAL score. Improved
HRQoL was reported by 13%, 15%, and 17% participants on the
BLCS, TOI, and TOTAL scores, respectively.
[(Fig._2)TD$FIG]
Fig. 2 – Mean change from baseline (with 99% confidence intervals) in BLCS score in the treatment comparisons: (A) chemotherapy comparison and (B)
radiotherapy comparison. B/L = baseline; BLCS = bladder cancer subscale; cRT = radiotherapy with chemotherapy; EoT = end of treatment;
RHDVRT = reduced high-dose volume radiotherapy; RT = radiotherapy; StRT = standard whole-bladder radiotherapy.
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fallen to 35%, 30%, and 29% in the BLCS, TOI and TOTAL
scores, respectively, with improvement reported in 29%,
34%, and 33%, respectively. On further follow-up, these
relative proportions remain fairly constant, with between
32% and 36% of patients reporting worsening on the BLCS
score (Fig. 4B), 28% and 36% on the TOI score, and 25% and30% on the TOTAL score, with similar numbers reporting
improvement.
No significant differencewas found between randomised
groups within each comparison in the proportions of
patients reporting clinically relevant improvement/wors-
ening on any scale or at any time point (Supplementary
Tables 5–10).
Table 2 – Change from baseline at 1 year for the randomised comparisons
cRT RT Difference cRT – RTa
1 yr N Meanb [122_TD$DIFF] 99% CI N Meanb [123_TD$DIFF] 99% CI Meanc 99% CId p value
BLCS 89 –0.59 –2.42, 1.24 88 –0.42 –2.27, 1.44 0.18 –1.60, 1.96d[124_TD$DIFF] 0.8
TOTAL 89 0.67 –4.56, 5.89 86 2.67 –2.46, 7.80 –1.79 –8.3, 4.72 0.5
TOI 88 –0.50 –4.45, 3.45 86 0.94 –3.08, 4.96 –1.07 –6.21, 4.07 0.6
EWB 91 0.90 –0.26, 2.06 88 1.48 0.46, 2.51 –0.47 –1.68, 0.75 0.3
FWB 89 0.25 –1.54, 2.04 88 0.99 –0.69, 2.67 –0.67 –2.77, 1.44 0.4
SWB 88 –0.16 –1.80, 1.47 88 0.22 –1.12, 1.55 –0.30 –2.07, 1.48 0.7
PWB 91 –0.11 –1.33, 1.10 88 0.38 –0.89, 1.66 –0.54 –2.14, 1.07 0.4
stRT RHDVRT Difference stRT – RHDVRTa[125_TD$DIFF]
N Meanb 99% CI N Meanb 99% CI Meanc [126_TD$DIFF] 99% CId[127_TD$DIFF] p value
BLCS 52 0.31 –2.13, 2.74 52 1.06 –1.43, 3.55 2.01 –0.31, 4.33d [128_TD$DIFF] 0.089
TOTAL 53 2.09 –5.58, 9.75 53 5.71 –0.66, 12.07 6.29 –2.54, 15.12 0.064
TOI 52 0.01 –5.96, 5.98 52 1.79 –2.79, 6.38 4.05 –2.75, 10.85 0.12
EWB 54 1.27 –0.22, 2.76 52 1.98 0.78, 3.18 0.86 –0.52, 2.24 0.11
FWB 53 –0.12 –3.19, 2.94 53 0.26 –1.61, 2.14 1.21 –1.98, 4.39 0.3
SWB 53 0.21 –2.34, 2.76 51 0.41 –1.33, 2.16 1.21 –1.60, 4.02 0.3
PWB 54 –0.19 –2.13, 1.75 53 0.69 –0.54, 1.91 1.16 –0.84, 3.16 0.13
ANCOVA = analysis of variance; BLCS = bladder cancer subscale; CI = confidence interval; cRT = radiotherapy with chemotherapy; EWB = emotional well-being;
FWB = functional well-being; PWB = physical well-being; RHDVRT = reduced high-dose volume radiotherapy; RT = radiotherapy without chemotherapy;
stRT = standard whole-bladder radiotherapy; SWB = social well-being; TOI = Trial Outcome Index; TOTAL = FACT-BL total score.
a Positive differences favour experimental group (cRT or RHDVRT, respectively).
b Mean change from baseline at 1 year, within each group.
c Mean difference between groups, computed by ANCOVA and adjusted by alternate randomisation, radiotherapy fractionation schedule, and baseline score.
d 95% CI for comparison of primary endpoint change in BLCS at 1 year.
[(Fig._3)TD$FIG]
Fig. 3 – Individual items in the bladder cancer subscale of FACT-BL. BL = baseline; EoT = end of treatment; FACT-BL = Functional Assessment of Cancer
Therapy—Bladder.
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[(Fig._4)TD$FIG]
Fig. 4 – Impact of treatment on individuals. (A) Proportion of patients with clinically significant changes in BLCS, TOI, and TOTAL—overall population.
Clinically significant changes are defined as changes from baseline above (better) or below (worse) the subscale threshold (BLCS  3 points,
TOI  5 points, TOTAL  7 points) at each time point. Patients without clinically significant changes are not shown in the figure. (B) Waterfall plot of
the absolute change in BLCS score from baseline at each time point, per randomised comparison. Each bar represents a patient. The dashed line
represents clinical significance (3). BLCS = bladder cancer subscale; cRT = radiotherapy with chemotherapy; EoT = end of treatment; FACT-
BL = Functional Assessment of Cancer Therapy—Bladder; RHDVRT = reduced high-dose volume radiotherapy; RT = radiotherapy without chemotherapy;
StRT = standard whole-bladder radiotherapy; TOI = Trial Outcome Index; TOTAL = FACT-BL total score.
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confirmed the results reported (results not shown).
4. Discussion
We report the largest study of patient-reported outcomes
after bladder-preserving treatment for MIBC. A key strength
is that these are, to our knowledge, the only such data
prospectively collected within a randomised controlled
trial. A drawback, however, is that not all patients returned
HRQoL questionnaires at the key defined time point, most
frequently due to prior recurrence or cystectomy, so it is
likely that the impact of recurrence is not fully captured in
these data. However, approximately 70% of patients
returned questionnaires at 1 year, which is similar to the
77% return rate observed in the cohort HRQoL study of Mak
et al [13]. Response rates declined further over time, though
~60% of expected questionnaires were received at 5 years. It
is likely that comorbidities and competing risks (including
death) would contribute to nonresponse in this elderly
population.
The results, as expected, show an early reduction in
HRQoL at the end of treatment consistent with treatment-
related toxicity; by 6 months, this has largely improved so
that mean scores return to baseline. The addition of
chemotherapy to radiotherapy did not affect the reported
HRQoL outcomes, providing evidence that the large
beneficial effect on locoregional control with chemora-
diotherapy using 5-FU andmitomycin C is achievedwithout
an appreciable adverse impact on HRQoL. Likewise, there is
no evidence that neoadjuvant chemotherapy impairs
HRQoL. If anything, there was a trend towards improved
HRQoL in these patients, though as baseline is taken after
neoadjuvant treatment, this may have impaired baselinescores and improvement could represent recovery from
neoadjuvant chemotherapy-related toxicity. Alternatively,
the debulking effect of the prior chemotherapy may have
left a better functioning bladder than one that has recently
undergone transurethral resection of bladder tumour,
resulting in improved radiation tolerance.
These results are in line with the limited previous data
available. Lagrange et al [14] investigated HRQoL using the
EORTC QLQ-C30 tool in 51 patients in a phase II
nonrandomised trial of 5-FU and cisplatin given during
whole pelvic radiotherapy. Similarly to our study, they
demonstrated a fall in HRQoL immediately after treatment,
which slightly improved above baseline across subscales
after 6 months. This is supported by other smaller studies
that report long-term HRQoL outcomes similar to popula-
tion averages [4–6,15]. The exception to this was emotional
wellbeing, which improved at the end of treatment and
beyond, perhaps emphasising the positive psychological
impact of receiving radical treatment and the support of
care providers, despite potential side effects.
Analysis of clinically relevant changes in HRQoL on an
individual basis perhaps provides a richer understanding of
the impact of treatment on patients. It is clear from this
analysis that the majority of patients experience some
deterioration in symptoms at the end of radiotherapy,
though many subsequently recover, and a substantial
proportion of patients have HRQoL similar to, or better
than, baseline over subsequent follow-up. The observation
of a mean overall score similar to baseline is thus achieved,
as roughly similar numbers of patients have improvement
and deterioration in quality of life. Similar findings have
been shown in previous studies. For example, Zietman et al
[4] reported in a retrospective study of 48 patients treated
with bladder-conserving therapy that patients had similar
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had reduced bladder compliance, two reported bladder
hypersensitivity, and seven were distressed by bowel
urgency. Likewise, Henningsohn et al [3] reported that
74% of patients had “little or no” urinary distress in a cohort
study of 58 patients after radiotherapy. In this study, 32% of
radiotherapy patients had some gastrointestinal symptoms
compared with 9% of population controls. Lagrange et al
[14] again reported that over 70% had “satisfactory” urinary
function after 6 months—a similar proportion to our study.
We can thus conclude from these data that though most
patients can expect satisfactory HRQoL after radiotherapy, a
subgroup will have a decline. Understanding the drivers of
this deterioration should be a priority in future HRQoL
research in bladder cancer. Can those patients likely to
experience a persistent decline in HRQoL be predicted from
baseline characteristics, tumour-related characteristics,
prior therapies (eg, BCG for prior non muscle invasive
bladder cancer), or even their baseline germline genetics?
Recently, a number of common genetic variants have been
associated with toxicity in prostate and breast radiotherapy
[16]; a study in bladder cancer patients would be of interest.
We also need to consider whether there are any interven-
tions that can be undertaken to moderate the impact of
radiotherapy treatment on HRQoL. For instance, there are
limited data suggesting that instillation of hyaluronic acid
may reduce radiation cystitis in gynaecological patients
[17].
It is disappointing that we could not demonstrate any
evidence of symptomatic or HRQoL improvement in the
group of patients treated with a modified radiotherapy
volume. This treatment approach was developed on the
basis that restricting the high-dose volume may reduce the
bladder shrinkage/fibrosis sometimes seen with whole-
bladder radiotherapy. This was supported by retrospective
studies suggesting that global bladder radiation tolerance
was less than focal tolerance [18]. Our study of this issue
was undermined by early closure of the radiotherapy
comparison randomisation due to slow recruitment and a
substantial number of protocol violations, resulting in low
power to assess treatment effects. Additionally, this study
was performed in the era before intensity-modulated and
image-guided radiotherapy, with the use of large margins
around the tumour so the amount of bladder sparing will
have been limited. Based on a successful pilot study [19], we
are currently revisiting this issue in conjunction with dose
escalation in a randomised phase II trial (RAIDER
ISRCTN26779187).
Chemoradiotherapy is a widely used bladder-conserving
alternative to radical cystectomy. This study does not
directly address the relative HRQoL benefits of surgery and
(chemo)radiotherapy. Indeed, given the very different
treatment modalities, making such a comparison is
challenging; for instance, a patient who has a radical
cystectomy and uteroileal bypass does not pass urine and
therefore reporting of urinary symptoms has a very
different interpretation. Several retrospective or cohort
studies suggest that HRQoL after radiotherapy is at least
equivalent and possibly superior to that followingcystectomy [5,20–24]. The largest of these is a cohort study
of 173 survivors of bladder cancer 7–9 years after
cystectomy or chemoradiotherapy, which reported better
HRQoL in most domains after chemoradiotherapy, though
this study is limited by a lack of baseline data [13]. One
aspect of this study was better sexual function after
chemoradiotherapy, which is supported by our data that
show, at worst, a modest decline in sexual function after
radiotherapy with or without chemotherapy.We previously
published a small randomised feasibility study of selective
bladder preservation and radical cystectomy (SPARE)
[15]. The patients who had radiotherapy had similar HRQoL
scores to those reported here, which, though not statisti-
cally significant, tended to be higher than those achieved by
patients having cystectomy.
5. Conclusions
This study shows that overall, after an initial fall immedi-
ately after treatment, HRQoL recovers to baseline levels and
is maintained at this level to 5 years for bladder cancer
patients treatedwith radiotherapy. Addition of concomitant
chemotherapy or use of neoadjuvant chemotherapy has no
significant impact on HRQoL, further supporting the routine
use of 5-FU and mitomycin C in this setting. Although the
majority of patients maintain HRQoL similar to or better
than baseline, around one-third experience some persistent
detriment. This has to be considered in the context of the
significant quality of life impact of the alternative treatment
of cystectomy.
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